These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 31653147)

  • 1. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
    S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R
    Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
    Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K
    Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas.
    Choi YL; Kang SY; Shin YK; Choi JS; Kim SH; Lee SJ; Bae DS; Ahn G
    Virchows Arch; 2006 Mar; 448(3):331-6. PubMed ID: 16315018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Detection of circulating hypermethylated tumor-specific RASSF1A DNA in ovarian cancer patients].
    Ma L; Liu FR; Zhang SL
    Zhonghua Bing Li Xue Za Zhi; 2005 Dec; 34(12):785-7. PubMed ID: 16545186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promoter Methylation of BRCA1, DAPK1 and RASSF1A is Associated with Increased Mortality among Indian Women with Breast Cancer.
    Yadav P; Masroor M; Nandi K; Kaza RCM; Jain SK; Khurana N; Saxena A
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):443-448. PubMed ID: 29480000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer.
    Kikuchi R; Tsuda H; Kanai Y; Kasamatsu T; Sengoku K; Hirohashi S; Inazawa J; Imoto I
    Cancer Res; 2007 Aug; 67(15):7095-105. PubMed ID: 17671176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylation profile of BRCA1, RASSF1A and ER in Vietnamese women with ovarian cancer.
    Vo LT; Thuan TB; Thu DM; Uyen NQ; Ha NT; To TV
    Asian Pac J Cancer Prev; 2013; 14(12):7713-8. PubMed ID: 24460357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA.
    Giannopoulou L; Chebouti I; Pavlakis K; Kasimir-Bauer S; Lianidou ES
    Oncotarget; 2017 Mar; 8(13):21429-21443. PubMed ID: 28206954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.
    Sahnane N; Carnevali I; Formenti G; Casarin J; Facchi S; Bombelli R; Di Lauro E; Memoli D; Salvati A; Rizzo F; Sessa F; Tibiletti MG
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. O6-Methyguanine-DNA Methyl Transferase (MGMT) Promoter Methylation in Serum DNA of Iranian Patients with Colorectal Cancer.
    Alizadeh Naini M; Kavousipour S; Hasanzarini M; Nasrollah A; Monabati A; Mokarram P
    Asian Pac J Cancer Prev; 2018 May; 19(5):1223-1227. PubMed ID: 29801405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer.
    Fiolka R; Zubor P; Janusicova V; Visnovsky J; Mendelova A; Kajo K; Lasabova Z; Plank L; Danko J
    Oncol Rep; 2013 Dec; 30(6):2878-86. PubMed ID: 24068440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of miR-200 family members as blood biomarkers for human and laying hen ovarian cancer.
    Choi PW; Bahrampour A; Ng SK; Liu SK; Qiu W; Xie F; Kuo WP; Kwong J; Hales KH; Hales DB; Wong KK; Norwitz ER; Chow CK; Berkowitz RS; Ng SW
    Sci Rep; 2020 Nov; 10(1):20071. PubMed ID: 33208870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hypermethylation of promoter region of RASSF1A gene in ovarian malignant epithelial tumors].
    Ma L; Zhang JH; Liu FR; Zhang X
    Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):657-9. PubMed ID: 16438885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer.
    Bondurant AE; Huang Z; Whitaker RS; Simel LR; Berchuck A; Murphy SK
    Gynecol Oncol; 2011 Dec; 123(3):581-7. PubMed ID: 21955482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of aberrant methylation of HOXA9 and HIC1 through multiplex MethyLight assay in serum DNA for the early detection of epithelial ovarian cancer.
    Singh A; Gupta S; Badarukhiya JA; Sachan M
    Int J Cancer; 2020 Sep; 147(6):1740-1752. PubMed ID: 32191343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of Cadherins Methylation in Ovarian Cancer: a Next Generation Sequencing Approach.
    Chmelarova M; Baranova I; Ruszova E; Laco J; Hrochova K; Dvorakova E; Palicka V
    Pathol Oncol Res; 2019 Oct; 25(4):1457-1465. PubMed ID: 30368729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoter hypermethylation of p16, BRCA1 and RASSF1A genes in triple-negative breast cancer patients from Serbia.
    Kozomara Z; Supic G; Krivokuca A; Magic Z; Dzodic R; Milovanovic Z; Brankovic-Magic M
    J BUON; 2018; 23(3):684-691. PubMed ID: 30003738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory Markers and Risk of Epithelial Ovarian Cancer by Tumor Subtypes: The EPIC Cohort.
    Ose J; Schock H; Tjønneland A; Hansen L; Overvad K; Dossus L; Clavel-Chapelon F; Baglietto L; Boeing H; Trichopolou A; Benetou V; Lagiou P; Masala G; Tagliabue G; Tumino R; Sacerdote C; Mattiello A; Bueno-de-Mesquita HB; Peeters PH; Onland-Moret NC; Weiderpass E; Gram IT; Sánchez S; Obon-Santacana M; Sànchez-Pérez MJ; Larrañaga N; Castaño JM; Ardanaz E; Brändstedt J; Lundin E; Idahl A; Travis RC; Khaw KT; Rinaldi S; Romieu I; Merritt MA; Gunter MJ; Riboli E; Kaaks R; Fortner RT
    Cancer Epidemiol Biomarkers Prev; 2015 Jun; 24(6):951-61. PubMed ID: 25855626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
    Hanley GE; McAlpine JN; Miller D; Huntsman D; Schrader KA; Blake Gilks C; Mitchell G
    BMC Cancer; 2018 Mar; 18(1):254. PubMed ID: 29506471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients.
    Sharma G; Mirza S; Parshad R; Srivastava A; Gupta SD; Pandya P; Ralhan R
    Life Sci; 2010 Jul; 87(3-4):83-91. PubMed ID: 20470789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.